To include your compound in the COVID-19 Resource Center, submit it here.

Tofacitinib: Phase III data

Top-line data from the double-blind, international Phase III ORAL Step (1032) trial in 399 patients who had an inadequate response to >=1 tumor necrosis factor (TNF) inhibitor showed that 5 and 10 mg twice-daily oral

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE